Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: A network meta-analysis

Clinical Therapeutics

Volumn 36, Issue 10, 2014, Pages 1443-1453.e9

  Zintzaras, Elias ^a,b   Miligkos, Michael ^b   Ziakas, Panayiotis ^c   Balk, Ethan M ^a   Mademtzoglou, Despoina ^b   Doxani, Chrysoula ^b   Mprotsis, Theodoros ^b   Gowri, Raman ^a   Xanthopoulou, Paraskevi ^b   Mpoulimari, Ioanna ^b   Kokkali, Chrysoula ^b   Dimoulou, Georgia ^b   Rodopolou, Paraskevi ^b   Stefanidis, Ioannis ^b   Kent, David M ^a   Hadjigeorgiou, Georgios M ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THESSALY   (Greece)

^c BROWN UNIVERSITY   (United States)

Author keywords

diabetes type 2; effectiveness; meta analysis; network; tolerability; treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; VILDAGLIPTIN; VOGLIBOSE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; CLINICAL EFFECTIVENESS; DIABETIC PATIENT; DISEASE DURATION; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTEMATIC REVIEW; AGONISTS; ANALYSIS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84908304763     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.06.035     Document Type: Review

References (28)

1. G. Danaei, M.M. Finucane, Y. Lu for the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 2011 31 40
2. N.M. Maruthur The growing prevalence of type 2 diabetes: increased incidence or improved survival? Curr Diab Rep 13 2013 786 794
3. L. Avery, D. Flynn, and A. van Wersch Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions Diabetes Care 35 2012 2681 2689
4. A.J. Garber, M.J. Abrahamson, J.I. Barzilay for the American Association of Clinical Endocrinologists AACE comprehensive diabetes management algorithm 2013 Endocr Pract 19 2013 327 336
5. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse for the American Diabetes Association (ADA)and European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
6. T. Bailey Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm Am J Med 126 2013 S10 S20
7. E. Zintzaras, C. Doxani, T. Mprotsis, C.H. Schmid, and G.M. Hadjigeorgiou Network analysis of randomized controlled trials in multiple sclerosis Clin Ther 34 2012 857 869
8. D.C. Ziogas, M. Voulgarelis, and E. Zintzaras A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly Clin Ther 33 2011 254 279
9. G.M. Hadjigeorgiou, C. Doxani, and M. Miligkos A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis J Clin Pharm Ther 38 2013 433 439
10. American Diabetes Association Standards of medical care in diabetes - 2009 Diabetes Care 32 Suppl 1 2009 S13 S61
11. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
12. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in metaanalysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
13. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9:1-134, iii-iv.
14. F. Song, Y.K. Loke, and T. Walsh Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews BMJ 338 2009 b1147
15. A. Whitehead Meta-Analysis of Controlled Clinical Trials 2002 John Wiley & Sons Ltd Chichester, UK
16. B.C. Wallace, C.H. Schmid, J. Lau, and T.A. Trikalinos Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data BMC Med Res Methodol 9 2009 80
17. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary. Endocr Pract. 2013;19:536-557.
18. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 1999 2005 2012
19. U.K. Prospective Diabetes Study Group UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes Diabetes Care 21 1998 87 92
20. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
21. Q. Zhao, and T.R. Marcy Incretin-based therapy compared with non-insulin alternatives in elderly patients with type 2 diabetes Consult Pharm 28 2013 515 518
22. C. Díaz de León-Castañeda, M. Altagracia-Martínez, and J. Kravzov-Jinich Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City Clinicoecon Outcomes Res 4 2012 57 65
23. M.J. Davies, B.D. Chubb, I.C. Smith, and W.J. Valentine Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus Diabet Med 29 2012 313 320
24. S. Klarenbach, C. Cameron, S. Singh, and E. Ur Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin CMAJ 183 2011 E1213 E1220
25. F. Song, D.G. Altman, A.M. Glenny, and J.J. Deeks Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses BMJ 326 2003 472
26. T. Lumley Network meta-analysis for indirect treatment comparisons Stat Med 21 2002 2313 2324
27. G. Lu, and A.E. Ades Assessing evidence inconsistency in mixed treatment comparisons J Am Stat Assoc 101 2006 447 459
28. V. Hasselblad Meta-analysis of multitreatment studies Med Decis Making 18 1998 37 43